Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
作者信息
Blasi F, Canonica G W, Miravitlles M
机构信息
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Cardio-thoracic unit and Cystic Fibrosis Adult Center Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
Department of Biomedical Science, Personalized Medicine Clinic: Asthma & Allergy - Humanitas Clinical and Research Center, Humanitas University - Rozzano (Milano), Milan, Italy.
出版信息
Respir Res. 2017 Feb 10;18(1):35. doi: 10.1186/s12931-017-0516-y.
Abstract
摘要
相似文献
1
Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?勘误：对于有症状的慢性阻塞性肺疾病（COPD）患者，阿地溴铵单药治疗或与长效β2受体激动剂（LABA）联合使用是否是合理选择？
Respir Res. 2017 Feb 10;18(1):35. doi: 10.1186/s12931-017-0516-y.
2
Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?对于有症状的慢性阻塞性肺疾病（COPD）患者，阿地溴铵单独使用或与长效β2受体激动剂（LABA）联合使用是否是合理的选择？
Respir Res. 2017 Jan 18;18(1):19. doi: 10.1186/s12931-017-0506-0.
3
Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.阿地溴铵/富马酸福莫特罗固定剂量复方制剂的长期安全性：慢性阻塞性肺疾病患者的一项为期1年的随机试验结果
Respir Med. 2016 Jul;116:41-8. doi: 10.1016/j.rmed.2016.05.007. Epub 2016 May 7.
4
Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.使用氟替卡松/沙美特罗联合用药的慢性阻塞性肺疾病患者与单独使用其他吸入性类固醇和支气管扩张剂的患者的生存率比较。
COPD. 2007 Jun;4(2):127-34. doi: 10.1080/15412550701341111.
5
Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP.阿地溴铵与福莫特罗联合使用可通过环磷酸腺苷（cAMP）抑制肺上皮细胞的重塑参数。
Pharmacol Res. 2015 Dec;102:310-8. doi: 10.1016/j.phrs.2015.09.010. Epub 2015 Nov 4.
6
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.溴化阿地溴铵/富马酸福莫特罗固定剂量复方制剂治疗慢性阻塞性肺疾病。
Expert Opin Pharmacother. 2013 Apr;14(6):775-81. doi: 10.1517/14656566.2013.776539. Epub 2013 Mar 9.
7
Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.慢性阻塞性肺疾病的症状变异性与控制：双重支气管扩张疗法的优势
Respir Med. 2017 Apr;125:49-56. doi: 10.1016/j.rmed.2017.03.001. Epub 2017 Mar 2.
8
Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.每日 2 次 400μg 溴化阿地溴铵与安慰剂和噻托溴铵对比治疗中重度 COPD 患者的疗效。
Chest. 2012 Mar;141(3):745-752. doi: 10.1378/chest.11-0406. Epub 2011 Sep 8.
9
Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).在 COPD 患者中使用每日两次阿地溴铵治疗 12 周的疗效和安全性（ACCORD COPD I）。
COPD. 2012 Apr;9(2):90-101. doi: 10.3109/15412555.2012.661492. Epub 2012 Feb 9.
10
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.阿地溴铵/福莫特罗与沙美特罗/氟替卡松治疗慢性阻塞性肺疾病的疗效和安全性：一项 3 期 COPD 研究。
Eur Respir J. 2016 Oct;48(4):1030-1039. doi: 10.1183/13993003.00216-2016. Epub 2016 Aug 4.
本文引用的文献
1
Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?对于有症状的慢性阻塞性肺疾病（COPD）患者，阿地溴铵单独使用或与长效β2受体激动剂（LABA）联合使用是否是合理的选择？
Respir Res. 2017 Jan 18;18(1):19. doi: 10.1186/s12931-017-0506-0.
Zotero 插件